PDE4D Allosteric Modulators for Treating Cognitive Impairment

Information

  • Research Project
  • 8278774
  • ApplicationId
    8278774
  • Core Project Number
    U01NS078034
  • Full Project Number
    1U01NS078034-01
  • Serial Number
    078034
  • FOA Number
    RFA-NS-12-002
  • Sub Project Id
  • Project Start Date
    6/15/2012 - 12 years ago
  • Project End Date
    5/31/2017 - 7 years ago
  • Program Officer Name
    CYWIN, CHARLES L
  • Budget Start Date
    6/15/2012 - 12 years ago
  • Budget End Date
    5/31/2013 - 11 years ago
  • Fiscal Year
    2012
  • Support Year
    01
  • Suffix
  • Award Notice Date
    6/8/2012 - 12 years ago

PDE4D Allosteric Modulators for Treating Cognitive Impairment

DESCRIPTION (provided by applicant): Alzheimer's disease (AD) is an increasing medical burden due to the aging demographics of the US population. The most common form of dementia among older adults, AD affects parts of the brain important for memory formation and retrieval, seriously impairing a person's ability to live independently and cope with daily activities. In collaboration with the NIH Blueprint Neurotherapeutics Program, we seek to develop phosphodiesterase Type 4 (PDE4) allosteric modulators for improving cognition in accordance with the Target Product Profile below. Ideally, the therapeutic will improve cognition in MCI patients and impact AD pathophysiology, thereby slowing conversion to probable AD. Drug PropertiesMinimum Acceptable ResultIdeal ResultPrimary Drug IndicationImprovement of cognition in persons with Mild Cognitive Impairment (MCI) due to probable ADSlowing of conversion from MCI to probable ADPatient PopulationPatients with MCI due to probable AD according to the NIAA/AA working group criteriaPatients with MCI due to probable AD according to the NIAA/AA working group criteriaDelivery ModeOralOralTreatment DurationChronicChronicRegimenOral, once dailyOral, once daily PUBLIC HEALTH RELEVANCE: With a growing elderly population in industrialized nations world-wide, drugs to treat Alzheimer's disease (AD) are a critical unmet medical need. We are seeking to develop a new treatment for AD based on allosteric modulation of phosphodiesterase 4D (PDE4D). Ideally, the treatment will reverse or stabilize cognitive decline due to AD.

IC Name
NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE
  • Activity
    U01
  • Administering IC
    NS
  • Application Type
    1
  • Direct Cost Amount
    200051
  • Indirect Cost Amount
    35355
  • Total Cost
    235406
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    853
  • Ed Inst. Type
  • Funding ICs
    NINDS:235406\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
    ZNS1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    TETRA DISCOVERY PARTNERS, INC.
  • Organization Department
  • Organization DUNS
    967529939
  • Organization City
    GRAND RAPIDS
  • Organization State
    MI
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    495033314
  • Organization District
    UNITED STATES